- The plant-based and GMP-compliant Cannabidiol (CBD) will be available to customers in EMEA.
- With this innovative ingredient, Brenntag is further expanding its API portfolio.
- The exclusive distribution partnership with Lipomed will cover over 30 countries in EMEA.
Brenntag, the global market leader in chemicals and ingredients distribution, today announced a new exclusive partnership with Lipomed, a Swiss life science company focused on niche pharmaceuticals for the treatment of rare diseases. This collaboration introduces CBD Pure API, a crystalline powder containing cannabidiol derived from plants to the Pharma sector in EMEA.
The plant extracts used to produce the Natural CBD Pure APIoriginate from a certified Swiss hemp of the genetics Cannabis sativa L.and are obtained through a gentle low-temperature extraction process. It contains over 98,5% pure CBD and has close to zero (≤0.10%) delta-9-tetrahydrocannabinol (THC), preservatives, and artificial additives. Unlike THC, which is known for its psychoactive effects, CBD is non-intoxicating and suitable to be used in non-narcotic pharmaceutical applications. Complying with international pharmaceutical standards, Natural CBD Pure API offers a reliable and high-quality solution for the pharmaceutical industry, including the production of customized formulations.
Christoph Conrad, Head of Industry Market Management APIs & Supplements at Brenntag Specialties, remarked: “Lipomed’s high purity CBD is a perfect addition to our API portfolio in EMEA. As Brenntag always strives to work with the best and most trustworthy partners and materials of the industry, there could not be a better fit than Lipomed. These products combine natural origin, highest purity, and Swiss pharma expertise. We are very proud of the trust and confidence we are receiving with this exclusive partnership, and we are sure that together we will create a significant contribution to the development of the pharmaceutical market in EMEA.”
Dr. Athanasios Zikopoulos, CEO of Lipomed AG, added: “We are delighted and proud to join forces with such a reputed and skilled partner as the Brenntag team for the commercialization and distribution of our Natural CBD Pure API in the EMEA region. This marks the beginning of a certainly fruitful cooperation that will benefit both parties and their customers.”
Dr. Athanasios Zikopoulos, CEO of Lipomed AG, added: “We are delighted and proud to join forces with such a reputed and skilled partner as the Brenntag team for the commercialization and distribution of our Natural CBD Pure API in the EMEA region. This marks the beginning of a certainly fruitful cooperation that will benefit both parties and their customers.”
About Lipomed:
Lipomed is a privately owned and internationally operating Swiss life science company. It is GMP/GDP and ISO 9001 certified, with a pharmaceutical production facility located in Arlesheim near Basel and a sister company in Germany at Weil am Rhein for commercialization of Lipomed's pharmaceutical products in the EU. Lipomed is dedicated to the research, development, manufacturing, and commercialization of API and ethical pharmaceuticals with a particular focus on haematology, oncology, and niche indications. As an ethical company, LIPOMED has high social values and is engaged in environmental protection through reduction of emissions, reducing its consumption and waste, reducing air pollution and promote circular economy principles.
